Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review

Bazeley, Jonathan; Wish, Jay B.

doi:10.1053/j.ajkd.2021.09.017

Cited by 25 publications

(18 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The level of blood Mn in dialysis patients decreased, and the level of blood Mn was independently correlated with the level of hemoglobin [ 196 , 197 ]. For iron deficiency in dialysis patients [ 198 ], many studies have been conducted and their results are relatively clear; hence, we will not repeat them here.…”

Section: Advances In Research On Trace Elements and Malnutritionmentioning

confidence: 99%

Progress in the study of nutritional status and selenium in dialysis patients

et al. 2023

View full text Add to dashboard Cite

Malnutrition is very common in patients with chronic kidney disease, especially in those on maintenance dialysis. Malnutrition is one of the major factors affecting survival and death of dialysis patients, and reducing their activity tolerance and immunity. There are numerous and interacting risk factors for malnutrition, such as reduced nutritional intake, increased energy expenditure, hormonal disorders, and inflammation. Selenium, in the form of selenoproteins, is involved in many physiological processes in the body and plays an important role in maintaining redox homeostasis. Oxidative stress and infection are very common in dialysis patients, and selenium levels in dialysis patients are significantly lower than those in the healthy population. It has been shown that there is a correlation between selenium levels in hemodialysis patients and their nutrition-related indicators, and that selenium supplementation may improve malnutrition in patients. However, further studies are needed to support this conclusion and there is a lack of basic research to further characterize the potential mechanisms by which selenium may improve malnutrition in dialysis patients. The purpose of this review is to provide a comprehensive overview of factors associated with malnutrition in dialysis patients and to describe the progress of research on nutritional status and selenium levels in dialysis patients.

show abstract

Section: Advances In Research On Trace Elements and Malnutritionmentioning

confidence: 99%

Progress in the study of nutritional status and selenium in dialysis patients

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Abbreviations: HSR, hypersensitivity reaction; IV, intravenous; 6H syndrome, high fibroblast growth factor 23, hypophosphatemia, hyperphosphaturia, hypovitaminosis D, hypocalcemia, and secondary hyperparathyroidism. Table based on information from Rosner et al., [ 7 ] Bazeley et al., [ 41 ] and Khan et al. [ 42 ] …”

Section: Clinical Application Of Ferumoxytol: Treatment Of Idamentioning

confidence: 99%

“…Table based on information from Rosner et al, [ 7] Bazeley et al, [ 41] and Khan et al [ 42] Table 3 also studied in hemodialysis patients, [45] gastrointestinal disease patients, [46] pediatric patients, [47] pregnancy patients, [48] IDA patients failed oral iron therapy or intolerant to oral iron, [38,49] and IDA patients of any etiology. [39,47] The results from these clinical trials all indicated that ferumoxytol had good efficacy, safety, and tolerance, which paved a solid basis for the U.S. FDA to approve supplementary new drug applications with expanded specifications to ferumoxytol in 2018.…”

Section: Efficacy and Safetymentioning

confidence: 99%

The Story of Ferumoxytol: Synthesis Production, Current Clinical Applications, and Therapeutic Potential

Long,

Li,

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Ferumoxytol, approved by the U.S. Food and Drug Administration in 2009, is one of the intravenous iron oxide nanoparticles authorized for the treatment of iron deficiency in chronic kidney disease and end‐stage renal disease. With its exceptional magnetic properties, catalytic activity, and immune activity, as well as good biocompatibility and safety, ferumoxytol has gained significant recognition in various biomedical diagnoses and treatments. Unlike most existing reviews on this topic, this review primarily focuses on the recent clinical and preclinical advances of ferumoxytol in disease treatment, spanning anemia, cancer, infectious inflammatory diseases, regenerative medicine application, magnetic stimulation for neural modulation, etc. Additionally, the newly discovered mechanisms associated with the biological effects of ferumoxytol are discussed, including its magnetic, catalytic, and immunomodulatory properties. Finally, the summary and future prospects concerning the treatment and application of ferumoxytol‐based nanotherapeutics are presented.

show abstract

“…Results of several randomized trials have shown that intravenously administered FCM rapidly improves hemoglobin levels and replenishes depleted iron stores in various populations of patients with iron deficiency anemia, including those with inflammatory bowel disease [ 13 ], heavy uterine bleeding [ 14 ], postpartum iron deficiency anemia [ 15 ], heart failure [ 16 ], and chronic kidney disease [ 17 ]. It is also well tolerated in clinical trials [ 13 , 14 , 15 , 16 , 17 ]. FCM is, therefore, an effective option in the treatment of iron deficiency anemia in patients for whom oral iron preparations are ineffective or cannot be administered.…”

Section: Introductionmentioning

confidence: 99%

“…Administered intravenously, it is effective in the treatment of iron deficiency anemia, delivering a replenishment dose of up to 1000 mg of iron during a minimum administration time of </= 15 min [ 13 , 14 , 15 , 16 , 17 ]. Results of several randomized trials have shown that intravenously administered FCM rapidly improves hemoglobin levels and replenishes depleted iron stores in various populations of patients with iron deficiency anemia, including those with inflammatory bowel disease [ 13 ], heavy uterine bleeding [ 14 ], postpartum iron deficiency anemia [ 15 ], heart failure [ 16 ], and chronic kidney disease [ 17 ]. It is also well tolerated in clinical trials [ 13 , 14 , 15 , 16 , 17 ].…”

Section: Introductionmentioning

confidence: 99%

Ferric Carboxymaltose and Erythropoiesis-Stimulating Agent Treatment Reduces the Rate of Blood Transfusion in Refractory Anemia

Gidaro

Delitala

Berzuini

et al. 2022

JCM

View full text Add to dashboard Cite

Background: Erythropoiesis-stimulating agents (ESAs) are used to treat refractory anemia (RA). Guidelines suggest iron supplementation for unresponsive patients, regardless of iron deficiency. The primary aim of this study was to evaluate the effect of iron supplementation with ferric carboxymaltose (FCM) on the reduction of red blood cell transfusion (RBCT) rate in transfusion-dependent RA patients. Methods: This was a prospective quasi-randomized study, wherein patients were randomly assigned into three groups: (A) ESAs alone, (B) ferric gluconate (FG) and ESAs, and (C) FCM and ESAs. Hemoglobin and ferritin levels, as well as the number of RBCTs at 4 and 28 weeks were compared. Economic evaluation was also performed. Results: A total of 113 RA patients were enrolled. In total, 43 were treated with intravenous FG and ESAs, 38 with FCM and ESAs, and 32 with ESAs alone. At both follow-ups, erythropoietic response was increased in those receiving iron as compared with those with ESAs alone (p = 0.001), regardless of the type of iron. At one month, ferritin levels were higher in the FCM and ESA groups (p = 0.001). RBCTs were lower in both iron groups. The less costly treatment strategy was FCM, followed by FG, and lastly ESAs. Conclusion: Addition of iron to ESAs in RA reduced RBCT requirement and improved hemoglobin values.

show abstract

Recent and Emerging Therapies for Iron Deficiency in Anemia of CKD: A Review

Cited by 25 publications

References 54 publications

Progress in the study of nutritional status and selenium in dialysis patients

Progress in the study of nutritional status and selenium in dialysis patients

The Story of Ferumoxytol: Synthesis Production, Current Clinical Applications, and Therapeutic Potential

Ferric Carboxymaltose and Erythropoiesis-Stimulating Agent Treatment Reduces the Rate of Blood Transfusion in Refractory Anemia

Contact Info

Product

Resources

About